Financial Reports: Jubilant LifeSciences FY12

Jubilant LifeSciences

4Q Revenues: $216.2 million

4Q Loss: $11.7 million

FY Revenues: $786.7 million

FY Earnings: $2.8 million

Comments: CMO operations, including the Jubilant HollisterStier operations, were up 17% year-on-year to $114 million in FY12. The Generics unit ballooned 161% to $98 million. Specialty Pharma was up 25% to $57 million. Drug Discovery & Development was up 16% to $45 million. The API business grew 33% to $83 million. The Pharmaceuticals unit overall posted revenues of $400 million, up 41%. The Life Science Ingredients Business was up 11% to $387 million. Extraordinary charges of $64 million wiped out most earnings for the year.